The growing need for treatments targeting individual conditions and diseases has led to the evolution of precision medicine. Currently, precision medicine is swiftly transforming the healthcare market with numerous key advancements and solutions. The revolutionizing capabilities of the solution are saving lives and opening unmatched opportunities for the market.
Given the industry’s bright prospects, solid precision medicine stocks Bristol-Myers Squibb Company (BMY), Regeneron Pharmaceuticals, Inc. (REGN), and Illumina, Inc. (ILMN) could be ideal portfolio additions in 2025.
